Abstract
Myasthenia gravis (MG) in the neonate is usually due to placentally transferred antibodies to the acetylcholine receptor (AChR), resulting in impaired neuromuscular transmission. It occurs in 10%-15% of newborns born to women with MG.We present a male newborn admitted to the neonatal intensive care unit (NICU) 38 hours after birth due to feeding difficulties and choking episodes. He was born to a mother with MG after an uneventful, well-followed pregnancy. Physical examination revealed a weak cry, persistent inability to fully close his eyelids, weak facial mimic, and a mouth that was always held open with swallowing and sucking difficulties. He assumed a frog leg position and showed generalized hypotonia with marked head lag. No respiratory distress was present. Laboratory evaluation showed an elevated anti-acetylcholine receptor antibody concentration (36.30 nmol/L; normal: <0.25 nmol/L). Transient neonatal myasthenia gravis (TNMG) was admitted, and an anticholinesterase agent was initiated. Given that he showed only a mild clinical improvement, two doses of immunoglobulin were administered on the eighth and ninth days of life. Anticholinesterase agents were progressively reduced and suspended on day 31 of life with clinical improvement. He was discharged home at one month of life clinically asymptomatic. He was evaluated one month later and was doing well.A positive history of MG in the mother associated with a suggestive physical examination may be sufficient to make the diagnosis of transient neonatal MG, emphasizing the importance of good medical history. With prompt diagnosis and appropriate management, most newborns experience spontaneous remission after a period of weeks to months.
Highlights
Transient neonatal myasthenia gravis (TNMG) is an antibody-mediated disorder caused by the transplacental transmission of maternal antibodies directed against the acetylcholine receptor (AChR) and, less frequently, muscle-specific kinase (MuSK), resulting in impaired neuromuscular transmission [1,2]
We report a case of a newborn with TNMG who needed feeding support and pharmacological treatment
Measurement of antibody levels is not routinely recommended in asymptomatic neonates born to Myasthenia gravis (MG) mothers, since there is no correlation between antibody levels and the onset of symptoms
Summary
Transient neonatal myasthenia gravis (TNMG) is an antibody-mediated disorder caused by the transplacental transmission of maternal antibodies directed against the acetylcholine receptor (AChR) and, less frequently, muscle-specific kinase (MuSK), resulting in impaired neuromuscular transmission [1,2]. A 2990 g newborn male, the second child of non-consanguineous parents, was transferred to the neonatal intensive care unit (NICU) 38 hours after birth due to feeding difficulties and choking episodes He was born to a 31-year-old G6P2A4 mother after an uneventful, well-followed pregnancy, in which the mother felt normal fetal movements. On day 22 of life, normal muscle tone and feeding tolerance were present, so pyridostigmine was progressively reduced until suspension on day 31 of life. Three days later, he was discharged home with anti-AChR antibody levels of 5.9 nmol/L. On follow-up one month later, he was asymptomatic with a normal neurological examination
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.